Nancy Kim1, Joseph V Agostini, Amy C Justice. 1. Department of Internal Medicine, Section of General Internal Medicine, School of Medicine, Yale University, Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516, USA. nancy.kim@yale.edu
Abstract
BACKGROUND: Although medication nonadherence may contribute to inadequate diabetes control, adherence is not routinely measured. Persistence, the continuous refill of medications, is one metric that could be integrated into clinical care if associated with glycemic control. OBJECTIVE: To characterize the association of persistence levels (non-, good, overpersistence) with hemoglobin A(1c) (A1C) over 1 year in newly medicated diabetics in the Veterans Administration. METHODS: Eligible veterans were > or =18 years and first filled a prescription for oral hypoglycemic agents (OHA) between January 1, 2000, and December 31, 2002. The date the OHA was first dispensed was defined as the baseline date. Subjects must have filled at least 1 prescription for any drug, but no diabetes medications, during the 12 months preceding the baseline date. Persistence was measured in days supply of medication over 365 days and defined as non- (<0.80), good (> or =0.8-1.10), and over- (>1.10) persistence. The main outcome measure was achieving goal A1C (< or =7.0%) after 1 year. RESULTS: A total of 56,181 veterans were included. Veterans were male (97%) and white (67%) with comorbid hypertension (58%) and hyperlipidemia (40%). Median age was 63 years, while median baseline A1C was 7.7%. Fifty-two percent of patients had good persistence; 25% were overpersistent. Good persistence was associated with achieving goal A1C (RR 1.07; 95% CI 1.06 to 1.09). The association of overpersistence with the same outcome (RR 0.95; 95% CI 0.94 to 0.97) was lower than good persistence, but higher than nonpersistence (RR 0.93; 95% CI 0.92 to 0.94). CONCLUSIONS: Good persistence was associated with glycemic control. Overpersistent patients were common and more likely than nonpersistent patients, but less likely than good persisters to attain goal A1C. Estimating these different strata of persistence may be useful in identifying patients at risk of poor glycemic control.
BACKGROUND: Although medication nonadherence may contribute to inadequate diabetes control, adherence is not routinely measured. Persistence, the continuous refill of medications, is one metric that could be integrated into clinical care if associated with glycemic control. OBJECTIVE: To characterize the association of persistence levels (non-, good, overpersistence) with hemoglobin A(1c) (A1C) over 1 year in newly medicated diabetics in the Veterans Administration. METHODS: Eligible veterans were > or =18 years and first filled a prescription for oral hypoglycemic agents (OHA) between January 1, 2000, and December 31, 2002. The date the OHA was first dispensed was defined as the baseline date. Subjects must have filled at least 1 prescription for any drug, but no diabetes medications, during the 12 months preceding the baseline date. Persistence was measured in days supply of medication over 365 days and defined as non- (<0.80), good (> or =0.8-1.10), and over- (>1.10) persistence. The main outcome measure was achieving goal A1C (< or =7.0%) after 1 year. RESULTS: A total of 56,181 veterans were included. Veterans were male (97%) and white (67%) with comorbid hypertension (58%) and hyperlipidemia (40%). Median age was 63 years, while median baseline A1C was 7.7%. Fifty-two percent of patients had good persistence; 25% were overpersistent. Good persistence was associated with achieving goal A1C (RR 1.07; 95% CI 1.06 to 1.09). The association of overpersistence with the same outcome (RR 0.95; 95% CI 0.94 to 0.97) was lower than good persistence, but higher than nonpersistence (RR 0.93; 95% CI 0.92 to 0.94). CONCLUSIONS: Good persistence was associated with glycemic control. Overpersistent patients were common and more likely than nonpersistent patients, but less likely than good persisters to attain goal A1C. Estimating these different strata of persistence may be useful in identifying patients at risk of poor glycemic control.
Authors: Branko Kopjar; Anne E B Sales; Sandra L Piñeros; Haili Sun; Yu-Fang Li; Ashley N Hedeen Journal: Am J Cardiol Date: 2003-11-01 Impact factor: 2.778
Authors: Manel Pladevall; L Keoki Williams; Lisa Ann Potts; George Divine; Hugo Xi; Jennifer Elston Lafata Journal: Diabetes Care Date: 2004-12 Impact factor: 19.112
Authors: Leonard M Pogach; Stephen A Brietzke; Claude L Cowan; Paul Conlin; Debby J Walder; Clark T Sawin Journal: Diabetes Care Date: 2004-05 Impact factor: 19.112
Authors: David J Taber; Kelly J Hunt; Cory E Fominaya; Elizabeth H Payne; Mulugeta Gebregziabher; Titte R Srinivas; Prabhakar K Baliga; Leonard E Egede Journal: Hypertension Date: 2016-07-11 Impact factor: 10.190
Authors: David J Taber; James N Fleming; Cory E Fominaya; Mulugeta Gebregziabher; Kelly J Hunt; Titte R Srinivas; Prabhakar K Baliga; John W McGillicuddy; Leonard E Egede Journal: Am J Nephrol Date: 2016-12-02 Impact factor: 3.754
Authors: Lyndsay A Nelson; Shelagh A Mulvaney; Tebeb Gebretsadik; Yun-Xian Ho; Kevin B Johnson; Chandra Y Osborn Journal: J Am Med Inform Assoc Date: 2015-07-17 Impact factor: 4.497
Authors: J Y Min; M R Griffin; J Chipman; A J Hackstadt; R A Greevy; C G Grijalva; A M Hung; C L Roumie Journal: Diabet Med Date: 2018-11-20 Impact factor: 4.359